Biogen Inc vs Logitech International SA — how do they compare? Biogen Inc trades at $204 (market cap $30.13B), while Logitech International SA trades at $104.61 (market cap $14.96B). The key difference: Biogen Inc is far larger — about 2× Logitech International SA's market cap, and Logitech International SA pays a 1.64% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | LOGI | |
|---|---|---|
Market Cap | $30.13B | $14.96B |
Sector | Health | Technology |
52-Week High | $216.63 | $126.69 |
52-Week Low | $128.93 | $85.84 |
Enterprise Value | $37.20B | $13.30B |
Dividend Yield | — | 1.64% |
Trailing returns across standard periods
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →